TY - JOUR
T1 - Role of C-Reactive Protein in Diabetic Inflammation
AU - Stanimirovic, Julijana
AU - Radovanovic, Jelena
AU - Banjac, Katarina
AU - Obradovic, Milan
AU - Essack, Magbubah
AU - Zafirovic, Sonja
AU - Gluvic, Zoran
AU - Gojobori, Takashi
AU - Isenovic, Esma
N1 - KAUST Repository Item: Exported on 2022-05-20
Acknowledged KAUST grant number(s): BAS/1/1059-01-01, FCC/1/1976-20-01, OSR#4129
Acknowledgements: This work was funded by the Ministry of Education, Science and Technological Development of the Republic of Serbia (Contract No. #451-03-9/2021-14/200017) and KAUST grant OSR#4129 (awarded to E.R.I. and V.B.B.), which also supported M.O. M.E. has been supported by the KAUST Office of Sponsored Research (OSR) Award no. FCC/1/1976-20-01, and TG by the King Abdullah University of Science and Technology (KAUST) Base Research Fund (BAS/1/1059-01-01).
PY - 2022/5/17
Y1 - 2022/5/17
N2 - Even though type 2 diabetes mellitus (T2DM) represents a worldwide chronic health issue that affects about 462 million people, specific underlying determinants of insulin resistance (IR) and impaired insulin secretion are still unknown. There is growing evidence that chronic subclinical inflammation is a triggering factor in the origin of T2DM. Increased C-reactive protein (CRP) levels have been linked to excess body weight since adipocytes produce tumor necrosis factor α (TNF-α) and interleukin 6 (IL-6), which are pivotal factors for CRP stimulation. Furthermore, it is known that hepatocytes produce relatively low rates of CRP in physiological conditions compared to T2DM patients, in which elevated levels of inflammatory markers are reported, including CRP. CRP also participates in endothelial dysfunction, the production of vasodilators, and vascular remodeling, and increased CRP level is closely associated with vascular system pathology and metabolic syndrome. In addition, insulin-based therapies may alter CRP levels in T2DM. Therefore, determining and clarifying the underlying CRP mechanism of T2DM is imperative for novel preventive and diagnostic procedures. Overall, CRP is one of the possible targets for T2DM progression and understanding the connection between insulin and inflammation may be helpful in clinical treatment and prevention approaches.
AB - Even though type 2 diabetes mellitus (T2DM) represents a worldwide chronic health issue that affects about 462 million people, specific underlying determinants of insulin resistance (IR) and impaired insulin secretion are still unknown. There is growing evidence that chronic subclinical inflammation is a triggering factor in the origin of T2DM. Increased C-reactive protein (CRP) levels have been linked to excess body weight since adipocytes produce tumor necrosis factor α (TNF-α) and interleukin 6 (IL-6), which are pivotal factors for CRP stimulation. Furthermore, it is known that hepatocytes produce relatively low rates of CRP in physiological conditions compared to T2DM patients, in which elevated levels of inflammatory markers are reported, including CRP. CRP also participates in endothelial dysfunction, the production of vasodilators, and vascular remodeling, and increased CRP level is closely associated with vascular system pathology and metabolic syndrome. In addition, insulin-based therapies may alter CRP levels in T2DM. Therefore, determining and clarifying the underlying CRP mechanism of T2DM is imperative for novel preventive and diagnostic procedures. Overall, CRP is one of the possible targets for T2DM progression and understanding the connection between insulin and inflammation may be helpful in clinical treatment and prevention approaches.
UR - http://hdl.handle.net/10754/678047
UR - https://www.hindawi.com/journals/mi/2022/3706508/
U2 - 10.1155/2022/3706508
DO - 10.1155/2022/3706508
M3 - Article
C2 - 35620114
SN - 1466-1861
VL - 2022
SP - 1
EP - 15
JO - Mediators of Inflammation
JF - Mediators of Inflammation
ER -
